|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
WO1999045777A1
(en)
*
|
1998-03-10 |
1999-09-16 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treatment of asthma
|
|
US6299875B1
(en)
|
1998-06-04 |
2001-10-09 |
Panacea Pharmaceuticals, Llc |
Methods to block IGE binding to cell surface receptors of mast cells
|
|
US6913749B2
(en)
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
|
AU2002213441B2
(en)
*
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
WO2004041863A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses therefor
|
|
EP1558645B1
(en)
|
2002-11-08 |
2011-07-27 |
Ablynx N.V. |
Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
|
|
EP1900753B1
(en)
|
2002-11-08 |
2017-08-09 |
Ablynx N.V. |
Method of administering therapeutic polypeptides, and polypeptides therefor
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
DE202006020194U1
(de)
*
|
2006-03-01 |
2007-12-06 |
Bioceuticals Arzneimittel Ag |
G-CSF-Flüssigformulierung
|
|
CA2676843A1
(en)
*
|
2007-01-29 |
2008-08-07 |
Valtion Teknillinen Tutkimuskeskus |
Method for producing novel ige based reagents
|
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
|
EP2052736A1
(en)
*
|
2007-10-26 |
2009-04-29 |
Nycomed Danmark ApS |
Parathyroid hormone formulations und uses thereof
|
|
BRPI0821591A2
(pt)
*
|
2007-12-21 |
2016-05-03 |
Inspiration Biopharmaceuticals Inc |
composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
|
|
BRPI0820819B1
(pt)
*
|
2007-12-21 |
2021-06-08 |
F. Hoffmann-La Roche Ag |
formulação de anticorpos humanizados b-ly 1 e seu uso
|
|
MX344559B
(es)
|
2008-04-29 |
2016-12-20 |
Ascendis Pharma As |
Compuestos de hormona de crecimiento humana recombinante unidos al peg.
|
|
CA2738243C
(en)
*
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
BRPI0919879A2
(pt)
|
2008-10-29 |
2016-02-16 |
Wyeth Llc |
métodos para purificação de moléculas de ligação a antígeno de domínio único
|
|
MX337432B
(es)
|
2009-12-15 |
2016-03-04 |
Ascendis Pharma As |
Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
CN102533704A
(zh)
*
|
2010-12-30 |
2012-07-04 |
上海雅心生物技术有限公司 |
即配即用型的胰蛋白酶制剂
|
|
PT2691112T
(pt)
*
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
CN107233569B
(zh)
*
|
2011-10-25 |
2021-08-31 |
普罗西纳生物科学有限公司 |
抗体制剂和方法
|
|
EP3689335A1
(en)
|
2013-09-27 |
2020-08-05 |
Hanmi Pharm. Co., Ltd. |
Sustained type human growth hormone preparation
|
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
|
SG11201703870UA
(en)
|
2014-11-18 |
2017-06-29 |
Ascendis Pharma Endocrinology Div As |
Novel polymeric hgh prodrugs
|
|
PT3220892T
(pt)
|
2014-11-21 |
2021-11-05 |
Ascendis Pharma Endocrinology Div A/S |
Formas de dosagem de hormona do crescimento de longa ação
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
WO2019019998A1
(zh)
*
|
2017-07-25 |
2019-01-31 |
江苏恒瑞医药股份有限公司 |
一种il-15蛋白复合物药物组合物及其用途
|
|
KR20220098056A
(ko)
*
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
CN110732023B
(zh)
*
|
2018-07-18 |
2023-06-16 |
江苏恒瑞医药股份有限公司 |
一种her2抗体药物组合物及其用途
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
AU2020233198B2
(en)
|
2019-03-04 |
2025-05-15 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
|
|
CN113827717A
(zh)
*
|
2020-06-23 |
2021-12-24 |
三生国健药业（上海）股份有限公司 |
抗her2单克隆抗体冻干制剂及制备方法
|
|
CA3185192A1
(en)
|
2020-07-10 |
2022-01-13 |
Sujun DENG |
Anti-ige engineered antibody and application thereof
|
|
TW202409078A
(zh)
*
|
2022-07-18 |
2024-03-01 |
中國大陸商蘇州創勝醫藥集團有限公司 |
穩定之包含抗gremlin1抗體的藥物製劑
|